Tsutani H, Imamura S, Ueda T, Yoshida H, Iwasaki H, Fukushima T, Yoshimura T, Toyooka S, Nakamura T
First Department of Internal Medicine, Fukui Medical School, Japan.
Intern Med. 1992 Mar;31(3):319-24. doi: 10.2169/internalmedicine.31.319.
The prophylactic efficacy of ofloxacin (OFLX) therapy was evaluated in 51 granulocytopenic episodes in 22 patients with hematological malignancies during post-remission chemotherapy in a prospective, randomized, controlled trial. Oral administration of OFLX plus amphotericin-B (AMPH) and polymyxin-B (PL) reduced episodes of fever and infection more than did the control regimen with PL and AMPH alone (p less than 0.01), and the reduction in the incidence of infection was evident even in patients showing severe granulocytopenia (p less than 0.01). Furthermore, the first fever after the onset of granulocytopenia in the OFLX regimen developed later than that in the control regimen (p less than 0.05). Clinically, the prophylactic efficacy was 92% for the OFLX regimen and 40% for the control regimen (p less than 0.01). These findings suggest that OFLX is a promising prophylactic agent following post-remission chemotherapy. Patient hemomyelogram findings similar to those of patients with other malignancies may imply that OFLX is widely effective in granulocytopenic patients taking aggressive chemotherapy.
在一项前瞻性、随机、对照试验中,对22例血液系统恶性肿瘤患者缓解期化疗期间发生的51次粒细胞减少症发作进行了氧氟沙星(OFLX)治疗的预防效果评估。口服OFLX加两性霉素B(AMPH)和多粘菌素B(PL)比单独使用PL和AMPH的对照方案更能减少发热和感染发作(p<0.01),即使在出现严重粒细胞减少的患者中,感染发生率的降低也很明显(p<0.01)。此外,OFLX方案中粒细胞减少症发作后的首次发热出现时间比对照方案晚(p<0.05)。临床上,OFLX方案的预防有效率为92%,对照方案为40%(p<0.01)。这些发现表明,OFLX是缓解期化疗后一种有前景的预防药物。患者的血液骨髓象结果与其他恶性肿瘤患者相似,这可能意味着OFLX对接受强化化疗的粒细胞减少患者具有广泛疗效。